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Introduction
Cell-based therapy is an exciting, emergent treatment frontier for cardiovascular repair that has seen a 
remarkable evolution over the last decade. Clinical studies have been published using different types 
of adult cells to treat the problems of acute and established myocardial infarction (MI), refractory 
coronary ischemia and both ischemic and non-ischemic cardiomyopathy. In this review, we will initially 
address the key issue of cell delivery to the myocardium, followed by an overview of past and present 
clinical experience in this fi eld.
Cell Delivery
The goal of any delivery approach is to transplant enough cells into the cardiac territory of interest, to 
maximize initial retention of cells within that area and achieve adequate local engraftment and function 
at this site. This is heavily infl uenced both by the type of cell being transplanted and the myocardial 
microenvironment. There are three basic strategies for directing cells to the heart: systemic therapy, 
focused coronary vascular infusion and direct myocardial injection.
Systemic therapy
Systemic administration of cell therapy can be accomplished either by (1) using growth factors to 
mobilize progenitor cells from bone marrow to the heart or (2) infusing cells into a peripheral 
vein.
In the early stages of MI healing, local and systemic chemoattractants and cell adhesion molecules 
are upregulated, including granulocyte-colony stimulating factor (G-CSF), stromal cell-derived factor 
1 (SDF-1) and stem cell factor (SCF) (Lee et al. 2000; Askari et al. 2003; Ma et al. 2005). These cyto-
kines encourage the mobilization of stem cells from tissues such as bone marrow and facilitate their 
migration to the damaged myocardium. This has also been observed to a lesser degree in ischemic 
cardiomyopathy (Askari et al. 2003). Usually, endogenous migration of circulating cells to the heart is 
not suffi cient to impact greatly on myocardial healing or to prevent deleterious ventricular remodeling 
(Shintani et al. 2001). However, researchers have attempted to artifi cially induce this process by the 
use of supra-physiologic doses of exogenous growth factors like GSC-F. G-CSF therapy may therefore 
provide indirect cardiovascular effects by mobilizing bone marrow cells (BMCs) and endothelial pro-
genitor cells (EPCs) to sites of myocardial injury where they promote and participate in neovasculariza-
tion. In addition, direct actions on the heart and vascular system have also been demonstrated following 
growth factor therapy in acute MI, chronic ischemia and cardiomyopathy. These include infl ammatory 
and scar-modifying effects, pro-angiogenic stimulation of endothelial and smooth muscle cells and 
anti-apoptotic protection of cardiomyocytes (Kovacic et al. 2007; Hu et al. 2007a). To date, functional 
outcomes have been encouraging, especially at a preclinical level, although there is evidence that effi cacy 
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may be superior when growth factor treatment is 
combined with actual cell transplantation (Kondoh 
et al. 2007). Several small-scale clinical studies 
applying G-CSF therapy alone or in combination 
with cellular therapy, have been performed in patients 
with chronic myocardial ischemia and acute MI, but 
are notable for the heterogeneity of their design and 
their results. Furthermore, safety concerns of 
increased coronary restenosis and acute coronary 
thrombosis have been raised (Kang et al. 2004).
Peripheral venous administration of cells has 
been used in animal models of MI (Bittira et al. 
2003; Barbash et al. 2003; Ma et al. 2005; Price 
et al. 2006). Despite limited retention of transplanted 
cells within the myocardium, these studies provided 
evidence of modest cardiac improvement. Non-
cardiac entrapment of cells is of particular concern 
with this approach, as highlighted by imaging stud-
ies that have made use of tracer molecule-labeled 
cells and SPECT, CT or MRI to track their engraftment 
(Gao et al. 2001; Chin et al. 2003; Barbash et al. 2003; 
Kraitchman et al. 2005). This may be especially prob-
lematic with adherent cell types such as mesenchymal 
stem cells (MSCs) (Aicher et al. 2003). Currently, a 
multi-center clinical trial in the United States is inves-
tigating the effectiveness and safety of intravenous 
MSC therapy in acute MI (Schuleri et al. 2007). In 
non-acute cardiac disease, intravenous delivery 
remains untested, although in this setting the lower 
expression of myocardial and systemic chemo-attrac-
tants is likely to hinder adequate cardiac engraftment 
of cells delivered peripherally.
Intracoronary infusion
Selective intracoronary administration of cell 
therapy achieves higher fi rst-pass delivery of cells 
to the site of myocardial injury, than is the case 
with systemic therapy. Unfractionated BMCs, 
MSCs and peripheral blood cells have all been 
delivered by coronary infusion in clinical trials of 
acute MI (Strauer et al. 2002; Assmus et al. 2002; 
Wollert et al. 2004; Chen et al. 2004; Bartunek et al. 2005), 
old MI (Assmus et al. 2006), ischemic cardiomy-
opathy (Boyle et al. 2006) and non-ischemic 
cardiomyopathy (Seth et al. 2006). Typically, cells 
are injected through the central lumen of an 
over-the-wire balloon catheter during transient 
balloon infl ations, which stop coronary blood fl ow, 
to prevent antegrade washout of cells and provide 
adequate exposure time to the microcirculation of 
the infarct-related vessel. In the context of recent 
MI where the culprit artery has been reperfused, this 
strategy is believed to enable cells to permeate 
across the damaged microvascular bed and distrib-
ute into the infarct territory and the adjacent peri-
infarct tissue. Peri-infarct cardiomyocytes are an 
important target of treatment as they are vulnerable 
to “demand” ischemia, hypertrophic change and 
apoptosis as part of the post-infarction remodeling 
process. The suitability of intracoronary cell deliv-
ery is not established for patients with chronic 
myocardial ischemia and non-ischemic cardiac 
disease. It is also contentious as to whether this 
approach is safe for the administration of large, 
adherent cell types (e.g. MSCs and SkMs), with 
MSC infusion reportedly causing microvascular 
obstruction and increased myocardial ischemia in 
two separate large animal studies (Vulliet et al. 2004; 
Freyman et al. 2006).
Intra-myocardial injection
Unlike intravascular infusion, direct intramyocardial 
injection targets specifi c regions of myocardium 
without relying on the upregulation of infl ammatory 
signals to assist transvascular cell migration and 
tissue invasion. Non-cardiac entrapment of the 
transplanted cells may also be reduced. This deliv-
ery approach appears suited to chronic myocardial 
disease, such as chronic ischemia or scarred myo-
cardium from old infarction, and also to the admin-
istration of MSCs and SkMs. Non-ischemic CMP 
may be another possible niche. While the safety of 
direct injection in recent MI awaits clinical 
evaluation, complications such as myocardial per-
foration have not been reported in animal studies 
(Amado et al. 2005; Freyman et al. 2006).
Direct injection can be achieved (1) transepi-
cardially during open chest surgery or via the 
coronary venous system or (2) transendocardially 
by percutaneous catheter-based techniques. 
Although these two injection strategies are likely 
comparable in their ability to disperse cells 
throughout the myocardial wall, relative compari-
sons have been limited and the long-term safety of 
direct cell injection requires evaluation (Gavira 
et al. 2006).
Transepicardial injection has been the common-
est route used in animal studies, where surgical 
exposure of the heart provides direct visualization 
for localizing injection sites and then tagging them 
for later histological analysis. Its invasiveness has 
restricted its clinical use to patients undergoing 
sternotomy for other cardiac surgery, such as in the 
early trials of autologous skeletal myoblast and 
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bone marrow therapy in patients having concurrent 
coronary artery bypass surgery (Menasche et al. 
2001b; Stamm et al. 2003).
The less invasive alternative for direct cell injec-
tion is percutaneous, catheter-based delivery. A 
variety of systems are now in use, sharing a multi-
component catheter design that consists of a core 
needle for cell delivery and a support catheter for 
directing the needle to the target sites for injection. 
The catheter is passed retrogradely across the aortic 
valve into the left ventricle, where intramyocardial 
injection takes place transendocardially. Adjunctive 
imaging is usually coupled to the catheter system to 
help select target sites for injection along the walls 
of the left ventricle. One such imaging modality is 
electromechanical mapping (NOGATM, Biologics 
Delivery Systems) which has been incorporated into 
the MyostarTM delivery system [Biologics Delivery 
Systems, Diamond Bar, CA, U.S.A.]. Electrome-
chanical mapping is used to create a color-coded map 
capable of characterizing areas of myocardium into 
normal, ischemic but viable or scarred and non-
viable. It has been validated against non-invasive 
imaging techniques, such as echocardiography, PET, 
SPECT and MRI and enables the identifi cation of 
myocardial segments that are suitable for cell ther-
apy, usually those that are poorly contractile but still 
viable (Kornowski et al. 1998; Botker et al. 2001; 
Keck et al. 2002; Perin et al. 2002). Electrome-
chanical mapping has now been used in preclinical 
and clinical studies of gene and cell therapy and has 
been especially useful in chronic ischemic cardio-
myopathy (Vale et al. 2000; Perin et al. 2003; Tse 
et al. 2003; Fuchs et al. 2003; Perin et al. 2004; 
Sherman et al. 2006; Tse et al. 2006). Serial mapping 
has been performed to demonstrate improvements 
in local contractility of hibernating myocardium 
following BMC transplantation (Perin et al. 2003). 
Other imaging modalities that have been used to 
guide catheter-based endomyocardial injection 
include conventional x-ray fl uoroscopy and real-time 
magnetic resonance imaging (Lederman et al. 2002; 
Dick et al. 2003; Barbash et al. 2004; Corti et al. 
2005). MRI is also capable of serial assessment of 
cardiac dimension and function, and advances are 
being made to enable its use for tracking the in vivo 
fate of stem cells that have been pre-labeled with 
ferromagnetic molecules (e.g. iron fl uorophores).
Another emerging strategy for direct delivery 
is transcoronary venous injection. Cells can be 
infused retrogradely into the coronary veins during 
balloon occlusion (Hou et al. 2005), or directly 
injected into the myocardium, transepicardially 
from a catheter placed inside a coronary vein 
(Thompson et al. 2003). The latter has been 
achieved using the TransAccess Delivery Sys-
temTM (Medtronic Vascular, Santa Rosa, CA, 
U.S.A.) which incorporates an intravascular ultra-
sound probe to locate structures. This system was 
trialed in a study of BMC injection in normal swine 
and a pilot study of SkM therapy in patients with 
ischemic cardiomyopathy (Thompson et al. 2003; 
Siminiak et al. 2005). This system may provide 
more direct access to the myocardium than coro-
nary artery infusion, particularly in the presence 
of occlusive coronary artery disease. Compared to 
transendocardial systems, transvenous injection 
needles probably have superior stability due to their 
parallel plane of approach to the myocardium, 
which allows them to deposit cells more deeply 
into the myocardium than is possible with the 
perpendicular plane of transendocardial injection 
(Thompson et al. 2003). Hence the needle tip is 
less likely to be dislodged by cardiac movement 
and by high pressure injections. The main limita-
tion of transvenous injection relates to potentially 
diffi cult engagement in tortuous and distal coro-
nary veins, although newer generation catheters 
have greater fl exibility to reduce this problem.
Determining the optimal delivery 
technique
The choice of delivery route is largely dependent 
on both the disease process requiring treatment and 
the type of cell to be transplanted (Fig. 1). 
Myocardial retention of cells is currently 
disappointing with both vascular and direct routes 
of administration, although some cell types (e.g. 
EPCs) may be more effectively retained than others 
(e.g. BMMNCs) (Wollert and Drexler, 2006). 
It remains diffi cult to establish which delivery 
system will fulfi ll most of the intended need as 
studies comparing the different systems are 
presently lacking. In a porcine study of MI-
reperfusion, radionuclide-labeled PB-derived 
MNCs were delivered by three different routes 
six days after induction of disease (Hou et al. 
2005). Intramyocardial injection outperformed 
intracoronary and retrograde coronary venous 
infusion in terms of myocardial retention (11%, 
2.6% and 3.2% respectively) and pulmonary 
entrapment (26%, 47%, 43% respectively) of cells, 
one hour after treatment. However, this was partly 
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offset by inconsistency in efficacy following 
treatment by direct injection. A separate study 
investigated MSC transplantation in the early 
stages of MI by intracoronary infusion, peripheral 
venous infusion and transendocardial injection 
(Freyman et al. 2006). While intracoronary 
administration achieved the highest levels of cell 
engraftment two weeks after treatment, it was also 
associated with high rates of coronary flow 
obstruction during MSC delivery and a considerable 
incidence of pulmonary entrapment of cells, 
compared to direct myocardial injection. Further 
comparative studies are required in the future, as 
delivery techniques evolve and become more 
sophisticated.
Clinical Trial Experience
The fi rst clinical trials of cell-based therapy in 
cardiac disease were published in 2001. Since then, 
the majority of trials have been phase I/II safety 
and feasibility studies utilizing either skeletal 
muscle cells or cells from bone marrow or blood 
in patients with MI, chronic coronary ischemia or 
cardiomyopathy.
Myocardial infarction
Cell therapy aims to attenuate infarct size and 
prevent signifi cant left ventricular remodeling after 
MI through the replacement of “lost” cardiomyo-
cytes and by protecting vulnerable cardiomyocytes 
in peri-infarct tissue. Much of this latter effect may 
be mediated by improving local tissue perfusion 
through neovascularization.
Numerous groups have investigated the safety 
and feasibility of intracoronary cell infusion, 4–7 
days after initial primary percutaneous revascular-
ization for MI (Assmus et al. 2002; Janssens et al. 
2006). Most commonly, the pragmatic strategies of 
using autologous unfractionated BMCs or peripheral 
blood cells (PBCs) have been adopted, avoiding the 
need for time-consuming ex vivo preparation of cells 
prior to treatment. A few groups have trialed more 
selective cell populations, including CD34+ EPCs 
and plastic-adhered, ex-vivo expanded MSCs.
Unfractionated bone marrow and blood-derived cells
Early studies demonstrated the safety and feasibility 
of intracoronary delivery of BMCs after MI 
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Figure 1. Tailoring Cell Type to Delivery Technique and Disease Process.
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2003; Fernandez-Aviles et al. 2004). Major com-
plications, such as aggravated myocardial ischemia 
or systemic inflammatory reaction were not 
observed in the short-term, nor were longer-term 
problems such as arrhythmia, intramyocardial 
calcifi cation, tumor formation or coronary reste-
nosis. Although not primarily designed to assess 
the effectiveness of BMC transplantation, there 
were some indications that treatment enhanced 
regional wall motion in the area of infarct and 
global left ventricular ejection fraction (LVEF). Of 
these initial studies, TOPCARE-AMI compared 
BMCs with PBCs (Assmus et al. 2002; Schachinger 
et al. 2004). LVEF improved in both groups by 
8%–9% from baseline to follow-up at four months 
and one year.
Randomized clinical trials of BM therapy in 
acute MI are summarized in Table 1. In the BOOST 
trial, 60 patients were randomized after successful 
primary intervention, to either coronary infusion of 
BMMNCs or non-placebo control (Wollert et al. 
2004). Recipients of cell therapy had a 6.7% 
improvement in LVEF, as determined by MRI, from 
post-MI baseline, compared to a 0.7% increase in 
controls. This improvement occurred in the context 
of full conventional medication therapy and notably 
was superior to the 3%–4% improvements in LVEF 
attributed to primary percutaneous reperfusion in 
the ADMIRAL and CADILLAC trials. Cell therapy 
did not result in signifi cant reductions in infarct size 
and left ventricular end-diastolic volume. By 18 
months of follow-up, mean LVEF had caught up in 
the control group, indicating that BMMNC treat-
ment had probably accelerated the recovery of 
cardiac function post-MI, that otherwise occurred 
more gradually with conventional treatment (Meyer 
et al. 2006).
In a study of similar size to the BOOST Trial, 
benefi ts of BMC therapy were restricted to infarct 
size, regional wall contractility and oxidative 
metabolism of severely infarcted territories 
(Janssens et al. 2006). Differences were not seen 
in follow-up LVEF or left ventricular volumes 
between recipients of cell therapy and placebo 
control. This may have been due to patients in this 
trial receiving earlier primary reperfusion after MI 
(3.7–4.1 hours compared to 8–9.8 hours in 
BOOST). Ejection fractions were well preserved 
at the time of enrolment (mean of approximately 
50%) and such patients had less scope for additional 
benefi t from adjuvant post-MI therapy than patients 
with more severe cardiac compromise.
The ASTAMI trial recruited patients with large 
anterior MI and reduced LVEF (mean 42%) 
(Lunde et al. 2006). One hundred patients were 
randomized to either BMC treatment given about 
6 days after MI, or non-placebo control. Cell 
therapy neither improved LVEF nor reduced left 
ventricular end-diastolic volume at six months, 
compared to the control group. In contrast the 
larger-sized REPAIR-AMI trial reported positive 
results with BMMNC therapy resulting in more 
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Abbreviations: RCT: randomized, controlled trial; RDBCT: randomized, double-blinded, controlled trial; mths: months; EF: left ventricular 
ejection fraction; MRI: magnetic resonance imaging; echo: transthoracic echocardiogram; SPECT: single photon electron computerized 
tomography; LVgram: left ventriculography; BMCs: bone marrow cells; BMMNCs: bone marrow mononuclear cells; RWM: regional wall motion; 
MACE: major adverse cardiac events. 
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LVEF improvement than placebo (5.5% vs 3%), 
especially in individuals with lower baseline LVEF 
(49%) and in those who received cell therapy at 
least fi ve days afer MI (Schachinger et al. 2006a; 
Schachinger et al. 2006b). This trial was also the 
fi rst to demonstrate clinical endpoint improve-
ments, with cell therapy resulting in lower com-
posite incidence of major cardiac events and 
mortality at twelve months, in patients already 
receiving optimal conventional treatment 
(Schachinger et al. 2006b).
The inconsistent results from trials of autolo-
gous BMC therapy refl ect inherent problems with 
this treatment strategy. In the fi rst instance, cardiac 
retention of BMCs is only modest (3%) after 
coronary delivery and may be higher and more 
extensive with transfer of selected cell populations, 
such as EPCs (Hofmann et al. 2005). In addition 
unfractionated BM preparations contain a low 
frequency of truly multipotent endothelial and 
mesenchymal progenitors and this limitation is 
accentuated in elderly patients and in those suffer-
ing from signifi cant illness and cardiovascular risk 
factors. It is unclear whether the large number of 
mature inflammatory cells accompanying BM 
infusion has a positive or deleterious effect on MI 
healing. Although the relationship between pro-
genitor cell content (dose) and effi cacy of therapy 
is not clearly defi ned, it is notable that compared 
to the negative ASTAMI trial, patients in the 
REPAIR-AMI study received 3–3.5-fold higher 
content of BMMNCs and CD34+ cells. This is 
despite the use of identical volumes of BM aspirate 
(50 mL) between the trials and reflects the 
observation that differences in the technique for 
BM collection and preparation may have a 
profound effect on the ultimate stem cell recovery 
(Seeger et al. 2007).
Selected cell populations
Fewer published trials have selectively used EPCs 
or MSCs for post-MI therapy (Chen et al. 2004; 
Bartunek et al. 2005; Boyle et al. 2005; Katritsis 
et al. 2005). CD34+ and CD133+ EPCs have been 
shown to possess a superior capacity for myocar-
dial homing and retention after intracoronary 
infusion than unfractionated BMMNCs (Hofmann 
et al. 2005). However, the cardiac reparative poten-
tial of these cells may be negatively infl uenced by 
adverse cardiac risk factors, such as smoking and 
diabetes, that compromise their clonogenic and 
differentiation potency (Numaguchi et al. 2006; 
Wojakowski et al. 2007).
In a control-matched study of 35 patients, 
autologous CD133+ EPCs were obtained from high 
volume (300 mL) BM aspirates and transplanted 
without ex vivo expansion, almost 12 days after 
MI (Bartunek et al. 2005). Treatment resulted in 
improvements in myocardial function, perfusion 
and viability, but was associated with higher rates 
of coronary in-stent reocclusion and restenosis.
Autologous MSC therapy has been applied 
post-MI in two published clinical trials, although 
the time required for in vitro preparation of these 
cells is obviously an obstacle to early infusion 
(Chen et al. 2004; Katritsis et al. 2005). This 
limitation will be overcome if clinical safety and 
effi cacy can be shown for allogeneic MSC trans-
plantation.
Chen et al. infused very high doses of autolo-
gous MSCs (48–60 × 109 cells) by coronary route 
18 days after primary intervention for MI (Chen 
et al. 2004). Six month follow-up results were 
favorable with a marked absolute increase in mean 
LVEF from 49% to 67% in the MSC group, com-
pared to 53% in the placebo group. Unfortunately 
detailed analysis of safety outcomes was not pro-
vided, despite the concerns that have arisen from 
preclinical studies showing complications from 
coronary infusion of this cell type. The study also 
failed to describe how such high numbers of MSCs 
were achieved in the relatively short period of time 
used to expand this population ex vivo.
It is noteworthy that in this study, the improve-
ments from MSC treatment occurred in spite of the 
2–3 week delay before cell delivery. Most other 
experience, particularly with unfractionated BMC 
therapy, has indicated that cell delivery is most 
effective between 4 and 7 days after MI (Janssens 
et al. 2006; Schachinger et al. 2006a; Hu et al. 
2007b). Earlier infusion of cells may cause exces-
sive obstruction and dysfunction of the microvas-
cular bed, while longer delays to therapy allow more 
cardiomyocytes to be lost through apoptosis and a 
greater time for scar development. Delayed intra-
coronary administration of a low-dose preparation 
of BM-derived MSCs and EPCs failed to achieve 
signifi cant myocardial benefi t in a small study of 
“old” anteroseptal MI (Katritsis et al. 2005). The 
ideal therapeutic window for cell delivery after MI 
may indeed differ between the various cell therapies 
currently available and remains an important issue 
requiring further clinical evaluation.
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Growth factor therapy
The use of G-CSF therapy for acute and chronic 
ischemic syndromes, with or without accompany-
ing coronary infusion of PBCs, is discussed in 
detail elsewhere (Kovacic et al. 2007). An early 
study from Kang et al. enrolled 27 patients who 
presented with MI too late for primary PCI. In this 
study patients only received coronary reperfusion, 
with bare metal stenting, once G-CSF therapy had 
been given for four days. Recipients of both G-CSF 
therapy and PBC infusion, but not G-CSF alone, 
exhibited improvements in exercise capacity, myo-
cardial perfusion and systolic function after six 
months (Kang et al. 2004). However, both groups 
receiving G-CSF had unexpectedly high rates of 
in-stent coronary restenosis at culprit lesion site, 
causing the trial to be terminated early. G-CSF 
therapy was also associated with adverse coronary 
outcome in a study of chronic ischemia, where 
acute thrombus formation and MI were observed 
(Hill et al. 2005).
More recently, The MAGIC Cell-3-DES trial 
demonstrated a 5% absolute improvement in 
LVEF, six months after G-CSF mobilization and 
intracoronary delivery of PBCs in patients with 
recent MI (Kang et al. 2006). The lack of 
treatment response in a second group of patients 
with older MI, indicates that this therapy has 
pro-vasculogenic effects that are no longer 
benefi cial once myocardial scarring is established. 
Patients in this study received drug-eluting stents 
and had no increase in restenosis as a complication 
of G-CSF.
Chronic coronary ischemia
The pro-angiogenic potential of BM-derived cells 
has led to their evaluation in several small-scale 
trials of patients suffering from refractory angina 
with no option for coronary revascularization. The 
goal of therapy in this scenario is to achieve 
improvement in myocardial perfusion and angina 
symptoms. Where myocardial hibernation has 
occurred with resultant cardiac dysfunction, cell-
derived neovascularization may also provide 
restoration of regional and global contractility.
In chronic coronary ischemia, there is thought 
to be a lack of the necessary local and systemic 
homing signals needed to entice cells to the 
myocardium from the vascular route. Consequently, 
direct myocardial injection of cells has typically been 
favored over intracoronary administration, especially 
in patients with occlusive, diffuse coronary disease 
not amenable to revascularization.
In a non-randomized trial of ischemic patients 
with marked reduction of LVEF (mean 20%), 
NOGA-guided transendocardial delivery of 
BMMNCs was performed safely and resulted in 
substantial improvements in reversible perfusion 
defects, regional and global myocardial function, 
including a 9% improvement in mean LVEF after 
four months (Perin et al. 2003). Clinical angina 
scores and physiological parameters of myocardial 
performance on exercise testing also improved. 
Symptomatic benefi ts were sustained at twelve 
months, as was myocardial perfusion; however, 
the improvements in ejection fraction were no 
longer signifi cant (Perin et al. 2004). In a smaller 
cohort of heart transplant candidates, cell therapy 
increased myocardial oxygen consumption to such 
an extent, that four out of fi ve patients no longer 
were eligible for transplantation (Silva et al. 2004). 
Arrhythmias were not observed as an adverse 
outcome in these trials, nor were there histological 
changes associated with abnormal cell growth or 
tissue lesions (Dohmann et al. 2005).
Comparable observations have been observed 
in similarly designed trials performed by other 
groups (Beeres et al. 2006; Fuchs et al. 2006). The 
non-randomized nature of these trials prohibits fi rm 
conclusions to be made about the efficacy of 
BMMNC injection in these patients. One important 
observation has been the great diversity in the 
functional properties of BMCs taken from different 
patients (Fuchs et al. 2006). This is a well-known 
phenomenon that emphasizes the limitations of 
autologous BMC therapy, especially in elderly 
patients and those with severe, chronic illness 
(Heeschen et al. 2004).
Recent trials of PBCs in chronic coronary 
disease have also demonstrated promise even 
when these cells were administered by coronary 
infusion (Ozbaran et al. 2004; Erbs et al. 2005; 
Boyle et al. 2006). Therapy with G-CSF-mobi-
lized circulating progenitor cells enhanced coro-
nary flow reserve, reduced infarct size and 
improved myocardial hibernation, in patients who 
had received recanalization of chronic total 
occlusions ten days earlier (Erbs et al. 2005). 
Mean LVEF increased from 51.7% to 58.9%, 
largely due to augmented wall contractility in the 
target region. These benefits may have been 
mediated by a combination of neovascularization, 
improved coronary endothelial function, paracrine 
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stimulation of endogenous cardiac stem cells and 
digestion of scar tissue by the release of proteases 
from the transplanted cells.
Post-MI cardiomyopathy
Patients with cardiac dysfunction who have late 
stage heart failure, represent a challenging group 
for clinicians. The limited donor supply of cadav-
eric hearts for transplantation has left a substantial 
need for the development of novel treatments that 
are capable of replacing the cardiac cell mass that 
is lost during ventricular remodeling. The replace-
ment of non-viable, scarred myocardium with 
functional, contractile heart tissue is a diffi cult 
objective especially as current adult cell therapies 
appear to be limited by poor engraftment after 
transplantation and inadequate regeneration of the 
damaged cellular components. Nevertheless, 
results from preliminary clinical trials have 
provided some evidence for cardiac repair from 
transplantation of SkMs or BM-derived cells in 
these patients. As discussed below, these small 
studies have been dogged by inconsistent results, 
making it diffi cult to confi dently draw conclusions 
regarding the effi cacy of these different cell types 
in post-MI cardiomyopathy.
Skeletal muscle cells
Skeletal myoblasts are attractive for repair of 
scarred myocardium because of their resistance to 
ischemia and fatigue and their contractile proper-
ties. Positive preclinical experience has been 
translated to the bedside by applying these myo-
genic precursors to patients with chronic cardiac 
dysfunction associated with ischemia and non-
viable scar (Menasche et al. 2001a; Menasche, 
2002; Pagani et al. 2003; Siminiak et al. 2004; Dib 
et al. 2005; Hagege et al. 2006). In these studies, 
SkMs were delivered either by direct transepicar-
dial injection, via sternotomy or the coronary 
venous route, or by percutaneous transendocardial 
injection (Smits et al. 2003). Initial results from 
non-randomized studies indicated promising aug-
mentation of contractile function, although a com-
mon confounder was the presence of concurrent 
bypass surgery (Menasche et al. 2003; Smits et al. 
2003; Herreros et al. 2003; Steendijk et al. 2006). 
Mechanistically, it has been shown that although 
engrafted myoblasts do not adopt a cardiac 
phenotype, they do retain their contractile proper-
ties in vivo and may upregulate their expression of 
slow-twitch myofi bers, which potentially imparts 
fatigue resistance (Pagani et al. 2003; Hagege et al. 
2003). A possible safety issue related to the use 
of SkM’s is arrhythmogenesis, as highlighted by 
the variable incidence of sustained ventricular 
tachycardia after therapy (Smits et al. 2003; 
Herreros et al. 2003). Causative mechanisms for 
this adverse outcome include the use of non-human 
serum during myoblast culture (Chachques et al. 
2004), failure of myoblasts to electrically couple 
with host cardiomyocytes, resulting in inhomoge-
neities in action potential conduction, and the 
possible creation of re-entry pathways by injection-
related disruption of myocardial anatomy.
The MAGIC trial (presented at American Heart 
Association 2006 Scientifi c Sessions, Chicago, 
Illinois) intended to recruit 300 patients with isch-
emic cardiomyopathy to assess the safety and 
effi cacy of two doses of autologous skeletal myo-
blasts, as compared to placebo. The study was 
terminated after enrolment of 97 patients because 
of slow recruitment and concerns about the study’s 
ability to meet effi cacy endpoints. The preliminary 
results indicated no difference among the three 
groups regarding major adverse events and 
ventricular arrhythmias, providing reassurance 
about the safety of intramyocardial myoblast injec-
tion. Primary efficacy endpoints pertaining to 
improvement in cardiac contraction were not met, 
although cautious optimism was drawn from 
secondary endpoint analysis which demonstrated 
reduction in left ventricular end-diastolic and 
end-systolic volumes with high dose cell therapy 
but not placebo.
Bone marrow and blood-derived cells
Autologous CD133+ and CD34+ cells have been 
injected in separate small series of patients with 
ischemic cardiomyopathy treated by concurrent 
CABG (Stamm et al. 2003; Patel et al. 2005). While 
global LVEF was enhanced in the majority of 
patients, it was likely that much of this effect was 
due to surgical revascularization, as there was not 
improvement in regional contractile function of 
the cell-treated scars. This reinforces that these 
cells are unlikely to achieve myocardial repair in 
regions of non-viable tissue, where there is little 
scope for benefi t from vasculogenesis.
Other studies utilizing unfractionated BMMNCs 
have yielded more encouraging results, possibly 
due to the myogenic potential of the small number 
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of mesenchymal precursors present in these 
populations. The non-randomized, controlled ICAT 
study enrolled 36 patients with chronic MI of at 
least nine months duration, and administered 
BMMNCs via intracoronary injection (Strauer 
et al. 2005). At three month follow-up, cell therapy 
resulted in signifi cant improvements in global 
LVEF, infarct size, myocardial viability and patient 
exercise capacity, to a much greater extent 
than observed in the control patients. Another 
randomized, controlled study of intramyocardial 
injection of BMMNCs demonstrated improvement 
in systolic thickening in cell-implanted scars but 
not untreated scars (Hendrikx et al. 2006). Six out 
of nine treated patients had inducible ventricular 
arrhythmia during electrophysiological testing at 
follow-up. While this is an isolated observation 
with BMMNC transplantation, it highlights the 
need for all clinical studies to perform rigorous 
safety analyses and report on longer-term adverse 
outcomes.
Non-ischemic cardiomyopathy
The playing fi eld and challenges for cell-based 
therapy are quite different in non-ischemic car-
diomyopathy, due mainly to differences in 
etiology, pathogenic mechanisms, and because of 
unique cellular and cytokine responses involved 
in the disease process. One example of this is a 
lack of upregulation of cardiac gene expression 
for several important stem cell homing factors in 
idiopathic dilated cardiomyopathy (Theiss et al. 
2007). This may account for the observation that 
patients with non-ischemic cardiomyopathy may 
have higher levels of CD34+ EPCs in peripheral 
blood, as in the absence of cardiac homing signals 
these cells fail to migrate and incorporate into the 
myocardium to assist with endogenous repair. 
Preclinical data in non-ischemic cardiomyopathy 
has focused on small animal models of toxic 
(doxorubicin-induced) or genetic cardiomyopathy, 
with promising results demonstrated for both 
SkMs and BM-derived cells (Agbulut et al. 2003; 
Kondoh et al. 2007; Ohnishi et al. 2007). Recently, 
myoblast transplantation also achieved functional 
benefi t in an ovine model of cardiomyopathy, 
induced by intracoronary doxorubicin (Borenstein 
et al. 2007).
Clinical application of cell treatment in non-
ischemic cardiomyopathy has lagged behind isch-
emic syndromes, although this is being addressed 
by trials such as the First-in-Man ABCD Trial (Seth 
et al. 2006) and TOPCARE-DCM. In the First-in-
Man ABCD trial, 44 patients with dilated non-
ischemic cardiomyopathy (LVEF  35%) were 
randomized to either non-placebo control or intra-
coronary administration of unfractionated 
BMMNCs. Six month results included improve-
ment in the functional class of heart failure and in 
mean LVEF by 5.4% (20 to 25%) in the treatment 
group, which was not observed in the control 
patients. Mechanistic uncertainty remains however, 
as endomyocardial biopsy specimens did not have 
evidence for persistence of the injected cells, pres-
ence of new immature cardiomyocytes, or increased 
infl ammation, infarction or neovascularization.
Conclusion
The fi eld of cardiovascular cell-based therapy has 
undergone remarkable growth over the last decade. 
On the basis of exciting preclinical discoveries, 
extension to clinical trials has been rapid. 
Unfortunately many questions still remain unan-
swered—questions that must be addressed if 
clinical application of cell transplantation is to 
become widely accepted and safely practiced. To 
date the great majority of clinical studies have 
involved the transfer of autologous unfractionated 
BMCs to the heart. While strengths of this strategy 
lie in its relative simplicity and therefore its scope 
for wide practice, it should be noted that it repre-
sents a “blanket” approach to cell therapy that does 
not enrich for the critical stem cell components of 
the bone marrow. A crucial step for future studies 
is to determine which cell product(s) are most 
effi cacious and safe at achieving myocardial repair 
in different patient groups. Follow-on questions 
such as optimal cell dose, method of delivery and 
timing of delivery also need resolution.
Much is still to be determined about stem cell 
biology and the mechanisms by which cardiac repair 
can be achieved and new strategies will no doubt 
seek to maximize the ability of cells to engraft, 
survive and function in vivo. By necessity there is 
still ground to cover through basic scientifi c and 
animal-based experiments. However, there is a 
considerable amount to be learned from well-
conducted, randomized clinical studies, in which 
appropriate subject groups and meaningful endpoints 
are chosen. Effi cacy of cell transplantation must be 
demonstrated by improvement in clinical endpoints, 
in patients who are “at-need” for adjuvant therapy 
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because of refractoriness to conventional treatment. 
These endpoints should include assessment of qual-
ity of life, readmission rates, adverse cardiac events 
and mortality. In addition, the long-term safety 
profi les of different cell types also need to be clari-
fi ed for specifi c disease cohorts. The performance 
and results of such carefully designed future studies 
will determine what role cell-based therapy may 
play in the future clinical management of patients 
with cardiovascular disease.
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